Multifocal motor neuropathy (MMN). This term is familiar to all MMN patients.
Conditions
Interventions
excitability-tests.
intravenous immunoglobilin
ion-channel
Multifocal motor neuropathy
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosis of MMN according to internationally accepted criteria of the European Federation of Neurological Societies and Peripheral Nerve Society (EFNS/PNS criteria). 2. One median nerve (left or right) with any of the following findings in the forearm segment: (a) conduction block, defined as segmental reduction of compound muscle action potential (CMAP) area of at least 30% or signs of demyelination: conduction velocity decrease up to 38 m/s or less and/or DML 5.3 ms or more and/or increased CMAP duration prolongation in the forearm of at least 30%; (b) motor axon loss defined as decreased CMAP amplitude of 3 mV or less; (c) normal conduction studies. 3. Treatment with IVIG. 4. Age range will be considered between 18 and 99 years.
Exclusion criteria
Exclusion criteria: 1. Other causes for neuropathy than MMN, including carpal tunnel syndrome (CTS). 2. Use of medication affecting peripheral nerve ion-channel currents.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the change in excitability parameters induced by IVIG infusion. This will be achieved by comparing excitability-parameters between the time of maximal weakness (just before the next IVIG infusion) and the time of maximal clinical improvement. . | — |
Secondary
| Measure | Time frame |
|---|---|
| To analyse the correlation between the degree of excitability changes after IVIG infusion, the presence of anti-GM1-antibodies and the degree of clinical improvement. | — |
Countries
The Netherlands
Outcome results
None listed